Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Akouos, Inc.

Surveyor Capital

Wu Capital

Cormorant Asset Management

Fidelity Management and Research Company

Novartis Venture Fund

Pivotal bioVenture Partners

Polaris Founders Capital

RA Capital Management

New Enterprise Associates

Akouos

We love spooky season! Check out these scenes from last month's Halloween party. Costumes were encouraged, and our team members showcased their incredible creativity.
 
The Best Costume Award went to Grace Cook, Samantha Davis took home the Most Original Costume Award, and Heather Devantier won the "I Wish I Had Thought of That" Award! Many thanks to all who participated and made the day so fun!
 
If you’re interested in joining the Akouos family, we encourage you to visit https://lnkd.in/g5w8FE6t to browse our current job openings and apply online.
 
#TeamAkouos #Halloween

Even the rain couldn’t keep the fun away! Members of our team and their families got together for a memorable fall outing at Kimball Farm. The team connected over a meal and drinks, ice cream, and some exhilarating bumper car action. Thank you to each and every one of you who came out to spend time together! Looking to be part of the Akouos team? Click the link below to explore our career opportunities!

#TeamAkouos

https://lnkd.in/g5w8FE6t

Celebrate the power of STEM with us this National STEM Day! Our mission of making healthy hearing available to all drives us forward every day. If you're looking for an opportunity to work on cutting-edge projects and contribute to meaningful advancements in medicine, explore our career openings and consider joining our dynamic team: https://lnkd.in/g5w8FE6t

#NationalSTEMDay #STEMDay #STEMImpact #STEMCommunity

Earlier this month, the Akouos team participated in the #Walk4Hearing! Each year we are honored to walk in solidarity with the deaf and hard of hearing community as we share our commitment to our mission to make healthy hearing available to all.

Click through to see some memories from this year’s walk and years past!


#NEWalk4Hearing

Akouos is excited to attend the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels, Belgium. We look forward to connecting with experts from around the world at these two engagements:

Aaron Tward, Chief Scientific Officer, will be presenting an update on “Considerations in the Development of a Gene Therapy for Otoferlin Gene-mediated Hearing Loss.”

Additionally, Katherine Gribble will be presenting on "The Efficiency of Multiplexing Guide RNAs for Multi-gene CRISPR/CaS9-based Genomic Modulation" at P696 during the poster sessions.
 
#ESGCT
 

	Dec '18	Dec '19	Dec '20	Dec '21
account payables	427K -	339K 20.61%	895K 164.01%	1.28M 43.02%
accumulated other comprehensive income loss	-60K -	-394K 556.67%	13K 103.30%	-202K 1,653.85%
cash and cash equivalents	23.02M -	25.08M 8.93%	68.93M 174.87%	121.91M 76.85%
cash and short term investments	23.02M -	25.08M 8.93%	308.01M 1,128.21%	232.45M 24.53%
common stock			3K -	3K 0%
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt			12.03M -	28.30M 135.34%
long term investments
net debt	-23.02M -	-11.29M 50.94%	-55.79M 393.98%	-92.93M 66.57%
net receivables
other assets
other current assets	319K -	1.06M 232.60%	2.63M 147.50%	3.71M 41.32%
other current liabilities	4.51M -	4.96M 10.07%	8.70M 75.31%	14.85M 70.71%
other liabilities
other non current assets	2.44M -	19.02M 680.91%	1.36M 92.84%	2.45M 79.74%
other non current liabilities	28.07M -	72.02M 156.56%
othertotal stockholders equity	214K -	717K 235.05%	58.97M 8,124.83%	402.24M 582.09%
preferred stock			333.35M -
property plant equipment net			21.35M -	40.14M 88.01%
retained earnings	-7.38M -	-33.12M 348.65%	-81.72M 146.72%	-168.40M 106.05%
short term debt		641K -	1.11M 73.95%	671K 39.82%
short term investments			239.08M -	110.55M 53.76%
tax assets
tax payables
total assets	25.78M -	45.16M 75.20%	333.35M 638.12%	278.75M 16.38%
total current assets	23.34M -	26.14M 11.98%	310.64M 1,088.40%	236.16M 23.97%
total current liabilities	4.93M -	5.94M 20.41%	10.71M 80.23%	16.80M 56.89%
total debt		13.78M -	13.14M 4.66%	28.98M 120.48%
total investments			239.08M -	110.55M 53.76%
total liabilities	33.01M -	77.96M 136.20%	22.74M 70.84%	45.10M 98.39%
total liabilities and stockholders equity	25.78M -	45.16M 75.20%	333.35M 638.12%	278.75M 16.38%
total non current assets	2.44M -	19.02M 680.91%	22.71M 19.40%	42.59M 87.51%
total non current liabilities	28.07M -	72.02M 156.56%	12.03M 83.30%	28.30M 135.34%
total stockholders equity	-7.23M -	-32.80M 353.74%	310.61M 1,046.97%	233.65M 24.78%

COM:AKOUOS

Akouos

Last Close

13.29

30/11 21:00

Volume Today

1.79M

Avg: -

Preview